Discovering and exploiting unique insights into protein stability

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology.

Year Invested: 2018
Location: Cambridge, MA

Recent News

June 28, 2018
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics

April 24, 2018
Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics

Read More News

Associated Team Members

Neil Exter

Sarah Larson
Partner/Chief Human Resources Officer

Craig Muir
Partner/Chief Technology Officer

Abbie Celniker, Ph.D.